Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Media Release Event to be held today in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...
-
Media Release Event to be held live in San Diego, CaliforniaIndependent experts to discuss data presented at the 2018 ASH Annual MeetingMeeting to be webcast live and archived on www.genmab.com ...
-
Company Announcement Copenhagen, Denmark; November 20, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will increase its share capital by 7,588 shares as a consequence of the exercise of employee...
-
Media Release Data from Phase III MAIA study in front line multiple myeloma accepted as Late-breaking Abstract for oral presentation at ASH Annual Meeting Copenhagen, Denmark; November 20, 2018 –...
-
Media Release CHMP issued positive opinion on split dosing regimen for DARZALEX Final decision from European Commission expected in the coming monthsOpinion supported by data from EQUULEUS...
-
November 14, 2018; Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2018 Highlights USD 1,441 million in net sales of DARZALEX® (daratumumab), resulting in royalty...
-
Media Release Copenhagen, Denmark; November 8, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the company’s CEO, Jan van de Winkel, Ph.D., will present an update at the Jefferies 2018...
-
Media Release Thirty-five total abstracts on Genmab owned and partnered programs scheduled for presentation at ASHThree abstracts related to Genmab owned programs: DuoBody®-CD3xCD20 &...
-
Company Announcement Phase III MAIA study of daratumumab in combination with lenalidomide and dexamethasone in front line multiple myeloma met the primary endpoint (PFS) at a pre-planned interim...
-
Company Announcement Phase III CASSIOPEIA study of daratumumab in combination with bortezomib, thalidomide and dexamethasone in front line multiple myeloma met the primary endpoint of stringent...